Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Zattarin, Emma; Presti, Daniele; Mariani, Luigi; Sposetti, Caterina; Leporati, Rita; Menichetti, Alice; Corti, Chiara; Benvenuti, Chiara; Fucà, Giovanni; Lobefaro, Riccardo; Ligorio, Francesca; Provenzano, Leonardo; Vingiani, Andrea; Del Vecchio, Marta; Griguolo, Gaia; Sirico, Marianna; Bernocchi, Ottavia; Marra, Antonio; Zagami, Paola; Agostinetto, Elisa; Jacobs, Flavia; Di Mauro, Pierluigi; Esposito, Andrea; Giorgi, Carlo Alberto; Lalli, Luca; Boldrini, Laura; Giacchetti, Pier Paolo Berton; Schianca, Ambra Carnevale; Guarneri, Valentina; Pedersini, Rebecca; Losurdo, Agnese; Zambelli, Alberto; Generali, Daniele; Criscitiello, Carmen; Curigliano, Giuseppe; Pruneri, Giancarlo; De Braud, Filippo; Dieci, Maria Vittoria; Vernieri, Claudio

doi:10.1038/s41523-023-00534-1

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors / Zattarin, E., Presti, D., Mariani, L., Sposetti, C., Leporati, R., Menichetti, A., Corti, C., Benvenuti, C., Fucà, G., Lobefaro, R., Ligorio, F., Provenzano, L., Vingiani, A., Del Vecchio, M., Griguolo, G., Sirico, M., Bernocchi, O., Marra, A., Zagami, P., Agostinetto, E., et al.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - ELETTRONICO. - 9:1(2023), pp. 27."-"-27."-". [10.1038/s41523-023-00534-1]